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required ethics approvals, yet the level of information required
varied considerably. Six of ten sites required the protocol, case
report form and an explanatory letter only. One of these sites
subsequently requested additional information resulting in a
delay of over two months. Another site allowed an expedited
review, but required supplementary forms totaling 42 pages.
Three sites required full ethics submissions. At six sites, a con-
tract was required, necessitating legal review and negotiation.
The remaining sites required a letter outlining the ﬁnancial
arrangements. The cost of the ethics processes ranged from
AU$500 to AU$3700. CONCLUSIONS: There is considerable
variability in the processes followed by Australian hospitals
when conducting chart audits which impacts on time and cost,
and must be taken into account when planning such a study.
Nevertheless, implementation of a well-planned chart audit
provides valuable information that will allow the development
of a strong cost-effectiveness argument.
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OBJECTIVES: Despite treatment advances, mCRC, the second-
leading cause of cancer-related deaths, imposes a substantial
burden to patients and public health. Panitumumab, a novel
therapeutic agent, is the ﬁrst fully human anti-EGFR mono-
clonal antibody and is currently approved as monotherapy for
patients expressing wild type (wt) KRAS, after failure of
ﬂuoropyrimidine-, oxaliplatin-, and irinotecan-containing che-
motherapy regimens. Panitumumab has introduced the concept
of individualised therapy in mCRC as it is indicated for patients
with speciﬁc KRAS gene, wt KRAS. This study evaluated the
overall budget impact (BI) of panitumumab on the total health
care budget in mCRC management in Greece. METHODS: A
decision analytic model estimating the cost associated with pani-
tumumab treatment and Best Supportive Care (BSC) was devel-
oped for the assessment of the BI for the Greek health care
system. Treatment costs included primary drug costs, infusion
costs, concomitant medications, clinic visits, hospitalisations and
radiation therapy. In the absence of local cancer registry, an
expert panel was used to map mCRC patient ﬂow. The cost
calculations were separately carried out for public and private
sectors. RESULTS: Out of 470 potentially eligible patients for
panitumumab monotherapy, the decision analytic model targets
268 (57%) patients with wt KRAS, according to the indication.
Panitumumab was calculated in addition to BSC. In the public
setting, the total panitumumab cohort budget was €4.8 million
and the average cost/patient treated €17,998. In the private
setting, the total panitumumab cohort budget was €5 and the
average cost/patient treated €18,716. CONCLUSIONS: Panitu-
mumab improves treatment outcomes and reduces unnecessary
exposure to therapy, with a modest health care budget impact. By
identifying the population of wt KRAS patients who are most
likely to beneﬁt, panitumumab increases patient-level clinical
outcomes and may lead to the rational use of health care
resources in Greece.
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OBJECTIVES: To determine whether Medicare Part D coverage
of prescription oral chemotherapeutics and a comparative
market basket of non-oncologics impacted trends in prescrip-
tion volume, retail price, and out-of-pocket costs. To assess
these trends over the 2005–2008 period, including the January
1, 2006 implementation of Medicare Part D. To investigate
geographic trends for states with and without major accredited
cancer centers (MACCs). METHODS: The top ﬁve prescribed
oral chemotherapeutics (capecitabine, imatinib, temozolomide,
chlorambucil, cyclophosphamide) and a comparative market
basket consisting of the top two prescribed anticonvulsants
(clonazepam, gabapentin), antidepressants (escitaprolam, ﬂuox-
etine), antipsychotics (quetiapine, risperidone), HIV/AIDS
(emtricitabine/tenofovir, ritonavir) and immunosuppressants
(azathioprine, mycophenolate) were selected based on total pre-
scriptions (TRx) between January 2005 and April 2008. For
that time frame, TRx, average retail price (ARP) and out-of-
pocket costs (OPC) per prescription for both Medicare Part D
patient and non-Part D Medicare patients were collected.
Finally, average TRx and ARP were compared in MACC states
versus non-MACC states over that time. Parameters were col-
lected using the Verispan’s VONA and VOPA databases. Sta-
tistical analyses were performed using one-way ANOVA.
RESULTS: Quarterly imatinib TRx increased signiﬁcantly more
than the other chemotherapeutics, >30% between Q1 2005 and
Q1 2008 (p < 0.05). This increase was mostly attributable to an
increase in reﬁlls, which was signiﬁcantly greater than the other
chemotherapeutics (p < 0.05). Interestingly, average TRx were
signiﬁcantly higher in MACC states (p < 0.05). The ARP sig-
niﬁcantly increased for capecitabine, imatinib and temozolo-
mide (33% average), while half of the comparative market
basket drugs saw an increase in ARP (30% average increase for
those 6; p < 0.05). With the exception of imatinib, the average
OPC was signiﬁcantly less for Medicare Part D patients than
for non-Part D patients (p < 0.05). Nonetheless, over time, the
OPC only increased signiﬁcantly for capecitabine and for two
of the market basket drugs (p < 0.05). CONCLUSIONS: The
introduction of Medicare Part D did not appear to impact ARP
or utilization for the top oral chemotherapeutics. One possible
explanation is Medicare Part B coverage of certain oral chemo-
therapeutics prior to January 1, 2006. Secondly, there may be
some drug classes that are more sensitive than others to
changes in health care policy. We observed a positive correla-
tion between MACC designation with utilization and ARP
patterns.
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OBJECTIVES: Determine how prostate cancer (PC) is diagnosed
in Spain as well as its economical impact on NHS budget.
METHODS: Cross sectional multicenter study conducted in
urology and specialized units in Spain during 2006. Information,
retrospectively compiled, from >18 years, 3 months—2 years
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